MSB 3.83% $1.26 mesoblast limited

Great sleuthing there. This will be untrue once Ryoncil gets...

  1. 426 Posts.
    lightbulb Created with Sketch. 91
    Great sleuthing there. This will be untrue once Ryoncil gets past the line. Physicians and parents will have something they've been waiting for so many years.

    Despite the setback, RBC Capital Markets analyst Brian Abrahams still believes Jakafi will eventually get its approval. Feedback from experts has been positive, “with physicians noting limited alternatives and clear signs of efficacy for the drug,” he wrote in a Wednesday note to clients. He projects the indication could get Jakafi over $300 million in U.S. peak sales.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.26
Change
-0.050(3.83%)
Mkt cap ! $1.432B
Open High Low Value Volume
$1.27 $1.30 $1.17 $21.32M 17.21M

Buyers (Bids)

No. Vol. Price($)
4 5460 $1.25
 

Sellers (Offers)

Price($) Vol. No.
$1.26 978 1
View Market Depth
Last trade - 16.10pm 24/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.